Compare Boston Scientific Corporation (BSX) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Boston Scientific Corporation trades at $51.65 (market cap $74.19B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $244.49 (market cap $46.84B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | TTWO | |
|---|---|---|
Market Cap | $74.19B | $46.84B |
Sector | Health | Media |
52-Week High | $108.14 | $262.29 |
52-Week Low | $42.63 | $189.69 |
Enterprise Value | $86.27B | $47.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
Take-Two Interactive (TTWO) trades at $244.33, down 3.64% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. Recent Q1 2026 earnings beat expectations, driven by NBA 2K and Grand Theft Auto performance, while the company maintains focus on the upcoming GTA VI launch in November 2026. Fundamentals show revenue growth to $5.63B in 2025, but net losses persist, with a negative net income margin of -4.79%.
The stock's upside potential is tied to GTA VI's success, with a consensus price target of $300.55 offering 23% upside. Key risks include execution on the high-stakes game launch, sustained profitability challenges, and competitive pressures in the gaming industry. Investor sentiment remains optimistic due to the blockbuster title's preorder momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
